Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2414-2422

  Joannides R ^a,b   Monteil, C ^b   De Ligny, B H ^c   Westeel, P F ^d   Iacob, M ^a   Thervet, E ^e   Barbier, S ^a   Bellien, J ^a,b   Lebranchu, Y ^f   Girardot Seguin, S ^g   Thuillez, C ^a,b   Godin, M ^a,b   Etienne, I ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g Laboratory Roche   (France)

Author keywords

Artery; Cyclosporine; Renal transplantation; Sirolimus; Stiffness

Indexed keywords

CATALASE; CYCLOSPORIN; ENDOTHELIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CAROTID TO FEMORAL PULSE WAVE VELOCITY; CENTRAL PRESSURE WAVE REFLECTION; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; OXIDATIVE STRESS; PARAMETERS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AORTA; BLOOD PRESSURE; CYCLOSPORINE; ENDOTHELIN-1; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; VASCULAR STIFFNESS;

EID: 84857189963     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03697.x     Document Type: Article

References (62)

1. Gill JS. Cardiovascular disease in transplant recipients: Current and future treatment strategies. Clin J Am Soc Nephrol 2008; 3(Suppl 2): S29-S37.
2. Favi E, Salerno MP, Romagnoli J, Castagneto M, Citterio F. Significant improvement in patient survival after renal transplantation in the last decade. Transplant Proc 2011; 43: 285-287.
3. Hirata K, Kawakami M, O'Rourke MF: Pulse wave analysis and pulse wave velocity: A review of blood pressure interpretation 100 years after Korotkov. Circ J 2006; 70: 1231-1239. (Pubitemid 44453213)
4. Nichols WW, O'Rourke MF. Wave reflections. In: Nichols WW, O'Rourke MF (eds.). McDonald's Blood Flow in Arteries-Theoretical, Experimental and Clinical Principles. 5th ed. London, United Kingdom: Arnold, 2005, pp. 201-222.
5. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605. (Pubitemid 44627304)
6. Barenbrock M, Kosch M, Jöster E, Kisters K, Rahn KH, Hausberg M. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20: 79-84. (Pubitemid 34913405)
7. Bahous SA, Stephan A, Barakat W, Blacher J, Asmar R, Safar ME. Aortic pulse wave velocity in renal transplant patients. Kidney Int 2004; 66: 1486-1492 (Pubitemid 39298381)
8. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-738. (Pubitemid 34252866)
9. London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438 (Pubitemid 34225679)
10. Strózecki P, Adamowicz A, Kozlowski M, Wlodarczyk Z,Manitius J. Long graft cold ischemia time is associated with increased arterial stiffness in renal transplant recipients. Transplant Proc 2009; 41: 3580-3584.
11. Strózecki P, Adamowicz A, Wlodarczyk Z,Manitius J. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients. Ren Fail 2007; 29: 679-684. (Pubitemid 47346984)
12. Gallego MJ, García Villalón AL, López Farre AJ, et al. Mechanisms of endothelial cell toxicity of cyclosporine A. Role of nitric oxide, cGMP, and Ca2+. Circ Res 1994; 74: 477-484.
13. Lungu AO, Jin ZG, Yamawaki H, Tanimoto T,Wong C, Berk BC. Cyclosporin A inhibits flow-mediated activation of endothelial nitricoxide synthase by altering cholesterol content in caveolae. J Biol Chem 2004; 279: 48794-48800. (Pubitemid 39625758)
14. Fréguin-Bouilland C, Godin M, Bellien J, et al. Protective effect of mycophenolatemofetil on endothelial function in an aortic allograft model. Transplantation 2011; 91: 35-41.
15. Akool el-S, Doller A, Babelova A, et al. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J Immunol 2008; 181: 2831-2845.
16. Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factorbeta1 concentration. Transplant Proc 2007; 39: 2138-2141. (Pubitemid 47418141)
17. Joannides R, Etienne I, Iacob M, et al. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 2010; 23: 1135-1143.
18. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991; 88: 310-314.
19. Ramzy D, Rao V, Tumiati LC, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: Comparative effects of rapamycin and cyclosporine. Circulation 2006; 114(Suppl I): I214-I219. (Pubitemid 44297153)
20. Flamant M, Tharaux PL, Placier S, et al. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17: 327-329.
21. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994; 23: 957-961. (Pubitemid 24180845)
22. Caló LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patientswith calcineurin inhibitor-induced hypertension: Effect of ramipril. J Cardiovasc Pharmacol 2002; 40: 625-631.
23. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Papachristodoulou A, Kostakis AI. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006; 38: 343-348 (Pubitemid 44138164)
24. Hussain SA, Hassan MQ, Zeki MA. Antioxidant profile of human erythrocytes after kidney transplantation. Clin Biochem 1995; 28: 607-610.
25. Simic-Ogrizovic S, Simic T, Reljic Z, et al. Markers of oxidative stress after renal transplantation. Transpl Int 1998; 11(Suppl 1): S125-S129. (Pubitemid 128683524)
26. Lexis LA, Richards RS, Fassett RG, Coombes JS. Cyclosporine A-induced changes to erythrocyte redox balance is time coursedependent. Basic Clin Pharmacol Toxicol 2005; 97: 135-140. (Pubitemid 41291209)
27. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579. (Pubitemid 26415078)
28. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478. (Pubitemid 39302636)
29. Chung AW, Yang HH, Kim JM, et al. Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: An exploratory study. Nephrol Dial Transplant 2010; 25: 4031-4041.
30. Kals J, Kampus P, Kals M, et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens 2006; 19: 902-908. (Pubitemid 46106988)
31. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16(Suppl 1): 121-124. (Pubitemid 32492523)
32. Zoungas S, Kerr PG, Chadban S, et al. Arterial function after successful renal transplantation. Kidney Int 2004; 65: 1882-1889. (Pubitemid 38591040)
33. Gelens MA, Christiaans MH, v Hooff JP. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Transplant Proc 2005; 37: 1900-1901. (Pubitemid 40790863)
34. Martínez-Castelao A, Sarrias X, Bestard O, et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc 2005; 37: 3788-3790. (Pubitemid 43015167)
35. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007; 22(Suppl 8): S61-S65.
36. Milliard S, Silva A, Blaise G, et al. Rapamycin's effect on vasomotion in the rat. Transplant Proc 1998; 30: 1036-1038. (Pubitemid 28309470)
37. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007; 116: 2726-2733. (Pubitemid 350291245)
38. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 2005; 112: 2002-2011. (Pubitemid 41377420)
39. Jabs A, Göbel S, Wenzel P, et al. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol 2008; 51: 2130-2138. (Pubitemid 351713680)
40. Budde K, Becker T, Arns W, et al. ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
41. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued mycophenolate mofetil. 4-year results of the POST-CONCEPT study. Am J Transplant 2011; 11: 1665-1675.
42. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
43. Maltete D, Bellien J, Cabrejo L, et al. Hypertrophic remodeling and increased arterial stiffness in patients with intracranial aneurysms. Atherosclerosis 2010; 211: 486-491.
44. Mitchell GF, Wang N, Palmisano JN, et al. Hemodynamic correlates of blood pressure across the adult age spectrum: Noninvasive evaluation in the Framingham Heart Study. Circulation 2010; 122: 1379-1386.
45. Crapo JD, McCord JM, Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol 1978; 53: 382-393.
46. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-126.
47. Delahousse M, Chaignon M, Mesnard L, et al. Aortic stiffness of kidney transplant recipients correlates with donor age. J Am Soc Nephrol 2008; 19: 798-805.
48. Ignace S, Utescu MS, De Serres SA, et al. Age-related and blood pressure-independent reduction in aortic stiffness after kidney transplantation. J Hypertens 2011; 29: 130-136.
49. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26: 2213-2219.
50. Posadzy-Malaczy ̃ nska A, Kosch M, Hausberg M, et al. Arterial distensibility, intima media thickness and pulse wave velocity after renal transplantation and in dialysis normotensive patients. Int Angiol 2005; 24: 89-94. (Pubitemid 43933055)
51. Ferro CJ, Savage T, Pinder SJ, Tomson CR. Central aortic pressure augmentation in stable renal transplant recipients. Kidney Int 2002; 62: 166-171. (Pubitemid 34754059)
52. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Buhaescu I, Covic M. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation 2003; 76: 1573-1577. (Pubitemid 37549829)
53. Verbeke F, Van Biesen W, Peeters P, Van Bortel LM, Vanholder RC. Arterial stiffness and wave reflections in renal transplant recipients. Nephrol Dial Transplant 2007; 22: 3021-3027. (Pubitemid 350093449)
54. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR; ACCT Investigators. Normal vascular aging: Differential effects on wave reflection and aortic pulse wave velocity: The Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46: 1753-1760. (Pubitemid 41531635)
55. Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance on cardiac efficiency and contractile function of in situ canine left ventricle. Circ Res 1992; 71: 490-502.
56. Kim SY, Hinkamp TJ, Jacobs WR, Lichtenberg RC, Posniak H, Pifarré R. Effect of an inelastic aortic synthetic vascular graft on exercise hemodynamics. Ann Thorac Surg 1995; 59: 981-989.
57. Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J AmColl Cardiol 2006; 47: 1622-1629.
58. Raichlin E, Prasad A, Kremers WK, et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients. Eur Heart J 2009; 30: 1356-1363.
59. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 2003; 41: 1253-1258. (Pubitemid 36706074)
60. Larose E, Behrendt D, Kinlay S, Selwyn AP, Ganz P, Fang JC. Endothelin-1 is a key mediator of coronary vasoconstriction in patients with transplant coronary arteriosclerosis. Circ Heart Fail 2009; 2: 409-416.
61. Haug C, Schmid-Kotsas A, Linder T, et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002; 103(Suppl 48): S76-S80.
62. Krötz F, Keller M, Derflinger S, et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007; 49: 201-208. (Pubitemid 46360361)